Development of a non-invasive screening tool to predict NAFLD

  • Research type

    Research Study

  • Full title

    Development of a screening tool to identify NAFLD in healthy Volunteers and patient populations

  • IRAS ID

    306287

  • Contact name

    Jorg Taubel

  • Contact email

    grants@richmondresearchinstitute.org

  • Sponsor organisation

    Richmond Research Institute

  • Clinicaltrials.gov Identifier

    NCT04873258

  • Duration of Study in the UK

    2 years, 0 months, 2 days

  • Research summary

    An increasing problem worldwide is a condition called non-alcoholic fatty liver disease (NAFLD), where the liver tissue becomes infiltrated with fat. This is a very variable condition, affecting up to 25% of the global adult population, and the effects can vary from very mild changes only visible on a scan without any health problems, all the way to liver inflammation, a condition called non-alcoholic steatohepatitis (NASH), liver scarring (cirrhosis) and even liver cancer. When we perform clinical trials of new medications a very common reason to stop or withdraw patients from these trials is liver reactions. It is recognised that patients with underlying fatty liver are more prone to these types of reactions, but it is very difficult to identify these patients without performing a scan or even a tissue sample to confirm the diagnosis, something which is expensive and difficult to do for every patient. We have new technology now, including a quick and harmless device to measure of body fat and skeletal muscle called bioimpedance vector analysis, as well as new technology to combine multiple factors from a single patient - including their age, sex, ethnicity, past medical history, blood tests and body measurements, with bioimpedance data, to better predict which patients may or may not have fatty liver. We can utilise artificial intelligence, also known as machine learning, to process this complex data into a simple formula or tool. Using this tool we would then be able to safely and more accurately screen volunteers for clinical trials, and allow safer and more effective development of new medications.

  • REC name

    West Midlands - Coventry & Warwickshire Research Ethics Committee

  • REC reference

    21/WM/0266

  • Date of REC Opinion

    16 Dec 2021

  • REC opinion

    Further Information Favourable Opinion